In a recent interview with ecancer, Prof. Fred Saad from the Centre hospitalier de l’Université de Montréal (CHUM) shared promising first-in-human results from the PAnTHa trial. The study highlights the potential of 225Ac-PSMA-trillium as a highly active and well-tolerated treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).
The trial marks a significant step forward in the field of radioligand therapy, specifically exploring the efficacy of alpha-emitting particles in treating advanced disease.
ecancer shared on X:
“First-in-human results from the PAnTHa trial show 225Ac-PSMA-trillium is well tolerated and highly active in metastatic castration-resistant prostate cancer (mCRPC).
Prof Fred Saad from CHUM speaks to ecancer.”
Watch the full interview with Prof. Fred Saad on ecancer.
Other articles about Prostate Cancer on OncoDaily.